TY - JOUR
T1 - Is it accurate to classify ALS as a neuromuscular disorder?
AU - van Es, Michael A
AU - Goedee, H Stephan
AU - Westeneng, Henk-Jan
AU - Nijboer, Tanja C W
AU - van den Berg, Leonard H
N1 - Funding Information:
MA Van Es received grants from the Netherlands Organization for Health Research and Development (Veni scheme), The Thierry Latran foundation, Motor Neurone Disease Association (MNDA), FIGHT-MND, the Netherlands ALS foundation (Stichting ALS Nederland), the EU Joint Programme —Neurodegenerative Disease Research (JPND), has received travel grants from Shire (formerly Baxalta), consulted for Biogen and currently serves on the ethical review board at the UMC Utrecht, The Netherlands. LH Van den Berg reports grants from Netherlands ALS Foundation, the Netherlands Organization for Health Research and Development (Vici scheme), the Netherlands Organization for Health Research and Development (SOPHIA, STRENGTH, ALS-CarE project), funded through the EU Joint Programme—Neurodegenerative Disease Research, JPND), served on the Scientific Advisory Board of Biogen, Cytokinetics, Prinses Beatrix SpierFonds, and the Latran Foundation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.
Publisher Copyright:
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9
Y1 - 2020/9
N2 - Introduction: Amyotrophic lateral sclerosis (ALS) is a fatal disorder characterized by the progressive loss of upper and lower motor neurons. ALS has traditionally been classified within the domain of neuromuscular diseases, which are a unique spectrum of disorders that predominantly affect the peripheral nervous system. However, over the past decades compounding evidence has emerged that there is extensive involvement of the central nervous system. Therefore, one can question whether it remains accurate to classify ALS as a neuromuscular disorder. Areas covered: In this review, the authors sought to discuss current approaches toward disease classification and how we should classify ALS based on novel insights from clinical, imaging, pathophysiological, neuropathological and genetic studies. Expert opinion: ALS exhibits the cardinal features of a neurodegenerative disease. Therefore, classifying ALS as a neuromuscular disease in the strict sense has become untenable. Diagnosing ALS however does require significant neuromuscular expertise and therefore neuromuscular specialists remain best equipped to evaluate this category of patients. Designating motor neuron diseases as a separate category in the ICD-11 is justified and adequately deals with this issue. However, to drive effective therapy development the fields of motor neuron disease and neurodegenerative disorders must come together.
AB - Introduction: Amyotrophic lateral sclerosis (ALS) is a fatal disorder characterized by the progressive loss of upper and lower motor neurons. ALS has traditionally been classified within the domain of neuromuscular diseases, which are a unique spectrum of disorders that predominantly affect the peripheral nervous system. However, over the past decades compounding evidence has emerged that there is extensive involvement of the central nervous system. Therefore, one can question whether it remains accurate to classify ALS as a neuromuscular disorder. Areas covered: In this review, the authors sought to discuss current approaches toward disease classification and how we should classify ALS based on novel insights from clinical, imaging, pathophysiological, neuropathological and genetic studies. Expert opinion: ALS exhibits the cardinal features of a neurodegenerative disease. Therefore, classifying ALS as a neuromuscular disease in the strict sense has become untenable. Diagnosing ALS however does require significant neuromuscular expertise and therefore neuromuscular specialists remain best equipped to evaluate this category of patients. Designating motor neuron diseases as a separate category in the ICD-11 is justified and adequately deals with this issue. However, to drive effective therapy development the fields of motor neuron disease and neurodegenerative disorders must come together.
KW - Amyotrophic lateral sclerosis (ALS)
KW - frontotemporal dementia (FTD)
KW - neurodegeneration
KW - TDP-43
UR - http://www.scopus.com/inward/record.url?scp=85090154316&partnerID=8YFLogxK
U2 - 10.1080/14737175.2020.1806061
DO - 10.1080/14737175.2020.1806061
M3 - Article
C2 - 32749157
SN - 1473-7175
VL - 20
SP - 895
EP - 906
JO - Expert Review of Neurotherapeutics
JF - Expert Review of Neurotherapeutics
IS - 9
ER -